Live
Alembic Pharmaceuticals‘s partner Breckenridge Pharma has launched desvenlafaxine succinate extended release tablets that are used in the treatment of major depressive disorder.
In June 2015, Alembic Pharma had received approval of its ANDA of desvenlafaxine succinate extended release tablets of strengths 50 mg and 100 mg.
Alembic Pharma has said in a regulatory filing that “The ANDA was filed as a Paragraph IV on the first-to file date and will share 180 day exclusivity with other ANDA first fillers.”
It further said that “The paragraph IV litigation was settled on terms that are confidential.”
